With the largest global diabetes population of 114 million people, China is facing rising healthcare costs associated with poor glucose control. Although one in ten people in China have diabetes, the country lacks the education and resources to improve diabetes management among such a large population.
With the evolution of China’s healthcare industry, Chinese health authorities are encouraging health information technology (IT) to provide solutions. As a medical technology industry leader, Medtronic has also expanded in this space.
In April 2016, we began a collaboration with Welltang – a leading provider of diabetes management services in China – to develop mobile health solutions that expand access to Medtronic therapies throughout China.
Together with Welltang, we can better engage with the Chinese diabetes population, leveraging our patient service expertise and technologies. We can also help build the link between physicians and their patients, enabling better diagnosis, treatment decisions, and integration of care. Through this novel collaboration, we will continue to identify pain points across the diabetes care continuum to develop more efficient disease management models that improve clinical and economic outcomes for patients, doctors, and health systems.
Thanks to our partnership, current Medtronic insulin pump customers can access up-to-date therapy information and education resources through Welltang’s diabetes app, aimed to help better manage glucose level using their pumps.
In addition, the 2 million+ users of the Welltang platform will be able to access information about our therapies and technologies through the app.
Finally, we are offering a new service program, “Life Pumped-up”, that provides Medtronic customers who are new to insulin pump therapy with the following:
- Customized pump training, education, and support
- Individualized payment plans
- Startup consumables package with quarterly delivery services
- Comprehensive risk assessment for diabetes complications
- Monthly A1C reports
As our first mobile health initiative in China, this collaboration marks a milestone for us to roll out similar initiatives in the region.
Welltang was founded in 2013 and is one of the leading providers of diabetes care management services in China with two widely-used apps for patients and physicians. Today, Welltang serves more than two million subscribers and over 11,000 endocrinologists on a daily basis.
, diabetes technology
, Global Access
, mobile health